Investor Presentation Full Year 2021
7
Investor presentation Full year 2021
Novo Nordisk®
International Operations diabetes sales grew across all regions,
mainly driven by GLP-1 performance
Reported diabetes sales and growth per IO geography
GLP-1 diabetes value market share and share of growth in IO
DKK
billion
60
14%
52%
45
Market
■Insulin I GLP-1 Growth at CER
share
NN GLP-1 market share
80%
-NN GLP-1 share of growth
74.0%
Geographical regions
60%
58.9%
12%
30
53.7%
40%
6%
I
38%
I
11%
Market share +5.2-%p vs. 2020
24%
15
73%
20%
2%
85%
8%
11%
0
0%
Nov
Nov
Nov
ΙΟ
EMEA
China
ROW
2019
2020
2021
Source: IQVIA MAT, Nov 2021 (Spot rate)
IO: International operations; NN: Novo Nordisk; pp: Percentage points; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; Row: Rest of WorldView entire presentation